Revance Therapeutics Long Term Debt 2012-2024 | RVNC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Revance Therapeutics long term debt from 2012 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Revance Therapeutics long term debt from 2012 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$178.6B
Regeneron Pharmaceuticals (REGN)	$127.1B
Vertex Pharmaceuticals (VRTX)	$125.3B
Gilead Sciences (GILD)	$103.1B
Bristol Myers Squibb (BMY)	$99.6B
CSL (CSLLY)	$97.7B
GSK (GSK)	$89.1B
Alnylam Pharmaceuticals (ALNY)	$34.1B
Argenex SE (ARGX)	$32.2B
BioNTech SE (BNTX)	$29.3B
Biogen (BIIB)	$28.5B
Moderna (MRNA)	$26.2B
Illumina (ILMN)	$20.6B
BeiGene (BGNE)	$19.3B
Genmab (GMAB)	$17.8B
BioMarin Pharmaceutical (BMRN)	$16.1B
Vaxcyte (PCVX)	$12.9B
Insmed (INSM)	$12.8B
Incyte (INCY)	$12.2B
Exact Sciences (EXAS)	$12.1B
Sarepta Therapeutics (SRPT)	$11.9B
Bio-Techne Corp (TECH)	$11.8B
QIAGEN (QGEN)	$10.6B
Legend Biotech (LEGN)	$9.2B
Bio-Rad Laboratories (BIO.B)	$9.1B
Roivant Sciences (ROIV)	$8.8B
Intra-Cellular Therapies (ITCI)	$8B
Halozyme Therapeutics (HALO)	$7.9B
Repligen (RGEN)	$7.8B
Exelixis (EXEL)	$7.5B